positiveSYS.SOURCE: Ars Technica• 2026-10-25T19:29:16Z
Moderna and Merck's Personalized mRNA Cancer Vaccine Demonstrates 42% Reduction in Mortality and Recurrence
Moderna and Merck's personalized mRNA cancer vaccine demonstrated a 42% reduction in mortality and recurrence among melanoma patients. The trial highlights the potential of mRNA-based immunotherapies in oncology treatment strategies.
*** END OF TRANSMISSION ***